by jtcir-auto | Nov 16, 2020 | Press Releases
– Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02 (“Study P02”) clinical trial costs for...
by jtcir-auto | Nov 16, 2020 | Press Releases
– Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02 (“Study P02”) clinical trial costs for...
by jtcir-auto | Nov 6, 2020 | Press Releases
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021- Continue to advance discussions to secure a commercialization partner for macimorelin in Europe and other key global markets- Ongoing evaluations...
by jtcir-auto | Nov 6, 2020 | Press Releases
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021- Continue to advance discussions to secure a commercialization partner for macimorelin in Europe and other key global markets- Ongoing evaluations...
by jtcir-auto | Sep 16, 2020 | Press Releases
– Recently secured funding bolsters cash runway to fund operations and provides significant optionality for growth- Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021-Ongoing evaluations to expand...